Cerulean Pharma Inc. (CERU) saw a big move last session, as the company’s shares fell by about 20% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for CERU, as the stock is now up nearly 7% since June 6.
This slump shouldn’t be too much of a surprise to investors, as the clinical-stage nanopharmaceutical producer has seen 1 negative revision in the past few weeks and its current year loss consensus has moved wider over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
CERU currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked stocks in the Medical-Drugs industry include Aeolus Pharmaceuticals Inc. (AOLS), Aerie Pharmaceuticals, Inc. (AERI) and Ariad Pharmaceuticals Inc. (ARIA). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
CERULEAN PHARMA INC (CERU): Free Stock Analysis Report
AEOLUS PHARMACEUTICL (AOLS): Free Stock Analysis Report
AERIE PHARMACEUTICALS INC (AERI): Free Stock Analysis Report
ARIAD PHARMACEUTICALS INC (ARIA): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry
- Finance Trading